Ari J Rosenberg1, Nishant Agrawal2, Alexander Pearson3, Zhen Gooi2, Elizabeth Blair2, John Cursio4, Aditya Juloori5, Daniel Ginat6, Adam Howard2, Jeffrey Chin3, Sara Kochanny3, Corey Foster7, Nicole Cipriani8, Mark Lingen8, Evgeny Izumchenko3, Tanguy Y Seiwert9, Daniel Haraf5, Everett E Vokes3. 1. Department of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, IL, USA. Electronic address: Arirosenberg@medicine.bsd.uchicago.edu. 2. Section of Otolaryngology-Head and Neck Surgery, University of Chicago, Chicago, IL, USA. 3. Department of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, IL, USA. 4. Department of Public Health Sciences, University of Chicago, Chicago, IL, USA. 5. Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA. 6. Department of Radiology, University of Chicago, Chicago, IL, USA. 7. Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN, USA. 8. Department of Pathology, University of Chicago, Chicago, IL, USA. 9. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Abstract
BACKGROUND: Favorable prognosis for Human papillomavirus-associated (HPV+) oropharyngeal cancer (OPC) led to investigation of response-adaptive de-escalation, yet long-term outcomes are unknown. We present expanded experience and follow-up of risk/response adaptive treatment de-intensification in HPV+ OPC. METHODS: A phase 2 trial (OPTIMA) and subsequent cohort of sequential off-protocol patients treated from September 2014 to November 2018 at the University of Chicago were reviewed. Eligible patients had T3-T4 or N2-3 (AJCC 7th edition) HPV+ OPC. Patients were stratified by risk: High-risk (HR) (T4, ≥N2c, or >10PYH), all others low-risk (LR). Induction chemotherapy (IC) included 3 cycles of carboplatin and nab-paclitaxel (OPTIMA) or paclitaxel (off-protocol). LR with ≥50% response received low-dose radiotherapy (RT) alone to 50 Gy (RT50). LR with 30-50% response and HR with ≥50% response received intermediate-dose chemoradiotherapy (CRT) to 45 Gy (CRT45). All others received full-dose CRT to 75 Gy (CRT75). RESULTS: 91 patients consented and 90 patients were treated, of which 31% had >10PYH, 34% had T3/4 disease, and 94% had N2b/N2c/N3 disease. 49% were LR and 51% were HR. Overall response rate to induction was 88%. De-escalated treatment was administered to 83%. Median follow-up was 4.2 years. Five-year OS, PFS, LRC, and DC were 90% (95% CI 81,95), 90% (95% CI 80,95), 96% (95% CI 90,99), and 96% (88,99) respectively. G-tube placement rates in RT50, CRT45, and CRT75 were 3%, 33%, and 80% respectively (p < 0.05). CONCLUSION: Risk/response adaptive de-escalated treatment for an inclusive cohort of HPV+ OPC demonstrates excellent survival with reduced toxicity with long-term follow-up.
BACKGROUND: Favorable prognosis for Human papillomavirus-associated (HPV+) oropharyngeal cancer (OPC) led to investigation of response-adaptive de-escalation, yet long-term outcomes are unknown. We present expanded experience and follow-up of risk/response adaptive treatment de-intensification in HPV+ OPC. METHODS: A phase 2 trial (OPTIMA) and subsequent cohort of sequential off-protocol patients treated from September 2014 to November 2018 at the University of Chicago were reviewed. Eligible patients had T3-T4 or N2-3 (AJCC 7th edition) HPV+ OPC. Patients were stratified by risk: High-risk (HR) (T4, ≥N2c, or >10PYH), all others low-risk (LR). Induction chemotherapy (IC) included 3 cycles of carboplatin and nab-paclitaxel (OPTIMA) or paclitaxel (off-protocol). LR with ≥50% response received low-dose radiotherapy (RT) alone to 50 Gy (RT50). LR with 30-50% response and HR with ≥50% response received intermediate-dose chemoradiotherapy (CRT) to 45 Gy (CRT45). All others received full-dose CRT to 75 Gy (CRT75). RESULTS: 91 patients consented and 90 patients were treated, of which 31% had >10PYH, 34% had T3/4 disease, and 94% had N2b/N2c/N3 disease. 49% were LR and 51% were HR. Overall response rate to induction was 88%. De-escalated treatment was administered to 83%. Median follow-up was 4.2 years. Five-year OS, PFS, LRC, and DC were 90% (95% CI 81,95), 90% (95% CI 80,95), 96% (95% CI 90,99), and 96% (88,99) respectively. G-tube placement rates in RT50, CRT45, and CRT75 were 3%, 33%, and 80% respectively (p < 0.05). CONCLUSION: Risk/response adaptive de-escalated treatment for an inclusive cohort of HPV+ OPC demonstrates excellent survival with reduced toxicity with long-term follow-up.
Authors: Phuc Felix Nguyen-Tan; Qiang Zhang; K Kian Ang; Randal S Weber; David I Rosenthal; Denis Soulieres; Harold Kim; Craig Silverman; Adam Raben; Thomas J Galloway; André Fortin; Elizabeth Gore; William H Westra; Christine H Chung; Richard C Jordan; Maura L Gillison; Marcie List; Quynh-Thu Le Journal: J Clin Oncol Date: 2014-11-03 Impact factor: 44.544
Authors: K Kian Ang; Jonathan Harris; Richard Wheeler; Randal Weber; David I Rosenthal; Phuc Felix Nguyen-Tân; William H Westra; Christine H Chung; Richard C Jordan; Charles Lu; Harold Kim; Rita Axelrod; C Craig Silverman; Kevin P Redmond; Maura L Gillison Journal: N Engl J Med Date: 2010-06-07 Impact factor: 91.245
Authors: T Y Seiwert; C C Foster; E A Blair; T G Karrison; N Agrawal; J M Melotek; L Portugal; R J Brisson; A Dekker; S Kochanny; Z Gooi; M W Lingen; V M Villaflor; D T Ginat; D J Haraf; E E Vokes Journal: Ann Oncol Date: 2019-10-01 Impact factor: 32.976
Authors: Brian O'Sullivan; Shao Hui Huang; Jie Su; Adam S Garden; Erich M Sturgis; Kristina Dahlstrom; Nancy Lee; Nadeem Riaz; Xin Pei; Shlomo A Koyfman; David Adelstein; Brian B Burkey; Jeppe Friborg; Claus A Kristensen; Anita B Gothelf; Frank Hoebers; Bernd Kremer; Ernst-Jan Speel; Daniel W Bowles; David Raben; Sana D Karam; Eugene Yu; Wei Xu Journal: Lancet Oncol Date: 2016-02-27 Impact factor: 41.316
Authors: Maura L Gillison; Andy M Trotti; Jonathan Harris; Avraham Eisbruch; Paul M Harari; David J Adelstein; Richard C K Jordan; Weiqiang Zhao; Erich M Sturgis; Barbara Burtness; John A Ridge; Jolie Ringash; James Galvin; Min Yao; Shlomo A Koyfman; Dukagjin M Blakaj; Mohammed A Razaq; A Dimitrios Colevas; Jonathan J Beitler; Christopher U Jones; Neal E Dunlap; Samantha A Seaward; Sharon Spencer; Thomas J Galloway; Jack Phan; James J Dignam; Quynh Thu Le Journal: Lancet Date: 2018-11-15 Impact factor: 79.321
Authors: Corey C Foster; Tanguy Y Seiwert; Ellen MacCracken; Elizabeth A Blair; Nishant Agrawal; James M Melotek; Louis Portugal; Ryan J Brisson; Zhen Gooi; Michael T Spiotto; Everett E Vokes; Daniel J Haraf Journal: Int J Radiat Oncol Biol Phys Date: 2020-04-18 Impact factor: 7.038
Authors: J K Salama; K M Stenson; E O Kistner; B B Mittal; A Argiris; M E Witt; F Rosen; B E Brockstein; E E W Cohen; D J Haraf; E E Vokes Journal: Ann Oncol Date: 2008-06-06 Impact factor: 32.976
Authors: Sue S Yom; Pedro Torres-Saavedra; Jimmy J Caudell; John N Waldron; Maura L Gillison; Ping Xia; Minh T Truong; Christina Kong; Richard Jordan; Rathan M Subramaniam; Min Yao; Christine H Chung; Jessica L Geiger; Jason W Chan; Brian O'Sullivan; Dukagjin M Blakaj; Loren K Mell; Wade L Thorstad; Christopher U Jones; Robyn N Banerjee; Christopher Lominska; Quynh-Thu Le Journal: J Clin Oncol Date: 2021-01-28 Impact factor: 44.544
Authors: Nancy Y Lee; Robert L Ferris; Amanda Psyrri; Robert I Haddad; Makoto Tahara; Jean Bourhis; Kevin Harrington; Peter Mu-Hsin Chang; Jin-Ching Lin; Mohammad Abdul Razaq; Maria Margarida Teixeira; József Lövey; Jerome Chamois; Antonio Rueda; Chaosu Hu; Lara A Dunn; Mikhail Vladimirovich Dvorkin; Steven De Beukelaer; Dmitri Pavlov; Holger Thurm; Ezra Cohen Journal: Lancet Oncol Date: 2021-04 Impact factor: 54.433
Authors: Ari J Rosenberg; Nishant Agrawal; Alexander T Pearson; Zhen Gooi; Elizabeth Blair; Louis Portugal; John F Cursio; Aditya Juloori; Jeffrey Chin; Kathryn Rouse; Victoria M Villaflor; Tanguy Y Seiwert; Evgeny Izumchenko; Mark W Lingen; Daniel J Haraf; Everett E Vokes Journal: Br J Cancer Date: 2022-08-09 Impact factor: 9.075
Authors: Jared H Hara; Stanley I Gutiontov; Sophia Uddin; Ari J Rosenberg; Alexander T Pearson; Zhen Gooi; Elizabeth A Blair; Nishant Agrawal; Everett E Vokes; Daniel T Ginat; Daniel J Haraf; Aditya Juloori Journal: Cureus Date: 2022-07-31